Original Article

Short Term Advantages of a Public-Private Partnership for Tuberculosis in Guinea Bissau: Reduction of Mortality and Increased Diagnostic Capacity

Fina Vieira¹, Mamadu Salieu Sanha¹,², Fabio Riccardi²,³ and Raffaella Colombatti²,⁴

¹ Hospital Raoul Follereau, Bissau, Guinea Bissau
² Aid, Health and Development-Onlus
³ Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy
⁴ Clinic of Pediatric Hematology-Oncology, Department of Maternal and Child Health, Azienda Ospedaliera-University of Padova, Padova, Italy

Correspondence to: Raffaella Colombatti. Clinic of Pediatric Hematology-Oncology, Department of Maternal and Child Health, Azienda Ospedaliera-University of Padova, Padova, Italy. Tel.+39-3455356570. E-mail: rcolambatti@gmail.com

Competing interests: The authors have declared that no competing interests exist.

Abstract. Background: Tuberculosis (TB) is widespread in Africa, but weak health systems in developing countries, often display poor quality of care with delays in case identification, irrational therapy and drug shortage, clinical mismanagement, unnecessary expenditures for patients, reduced adherence and increased mortality. Public-private partnership has demonstrated to increase TB case detection, but less is known about its effects on quality of care, mortality and costs for hospitalized TB patients.

Methods: Clinical outcomes and costs for TB patients at the TB National Reference Center of Bissau, in Guinea Bissau, West Africa, were determined during the first 5 months of the public-private management and compared to the ones of previous years when the hospitals was under direct Government’s management.

Results: 215 (2009-2010) and 194 (2012-2013) patients were admitted, respectively. Improvement (p<0.05) was observed in mortality reduction (21% vs 6%), cause of death determination (50% vs 85%), treatment abandonment (15 vs 1). Direct costs for patients during TB diagnostic pathway and inpatient care were significantly reduced, 475 vs. 0 USD.

Conclusions: Public-private partnerships displays significant short term benefits in National TB reference centers, even in post-conflict countries. Further studies could aid in determining the overall long term benefits of this type of cooperation, and the specific characteristic of TB and concomitant hematologic and infectious diseases in TB admitted patients.
Introduction. Tuberculosis (TB) treatment has saved more than 2 million people since 1995. Nevertheless, too many are not diagnosed, not treated or not properly treated. Public-private partnership has increased Tuberculosis (TB) case detection in different contexts. Weak health systems in developing countries, often display poor quality of care, delays in case identification, irrational therapy and drug shortage, unnecessary expenditures for patients and increased mortality. Despite a policy of free drug treatment, TB health services in many countries charge all income groups, costs are high and adherence measures are inadequate. Patients’ costs can be particularly burdensome for TB affected households in Africa.

Guinea-Bissau, in West Africa, has been experiencing annual military coups since the 1999 civil war. The country’s health indicators are among the worst in Africa. Proportion of budget spent on health is 2% of GDP, with total dependence on external financial support to the budget of the Health Ministry. The payment of salaries to health workers has often been subject to delay, and morale is poor.

TB incidence is 242/100,000. Case detection rate for all forms of TB, at 48%, has been declining since it reached 81% in 1995, indicating a decline in programmatic performance. The treatment success rate, for smear-positive TB (60%) and other forms (about 55%) is low.

The TB National Program operates through the National Reference Center in Bissau, Hospital Raoul Follereau (HRF), Regional Hospitals in the Regions and TB Health Centers throughout the country. According to the National Guidelines, TB patients in poor clinical conditions or with severe disease are admitted to the HRF, after referral from regional hospitals or health centers.

The National Reference Center for Tuberculosis and Lung Diseases, HRF, is an 115 bed hospital which includes an in-patient service (three words: men, women and children), an outpatient service, laboratory, two X-Ray Units, a pharmacy, service area (kitchen, laundry, ironing) and two cafeterias. Since October 1st 2012 the Health Ministry has entrusted the management of the HRF to the International Organization, Aid, Health and Development (AHEAD). The Government would give TB drugs received from international donors, pay the staff salaries and provide electricity. AHEAD would supply a top-up for the personnel and the diagnostic and treatment pathway for free to inpatients (including exams, non-specific drugs, food). The public hospital would be managed by the private sector, but within the framework of the National TB Program. It was hoped that this public-private partnership would improve the quality of diagnosis and treatment of TB suspects, increase adherence while reducing mortality and costs.

Methods. According to the National Guidelines, as part of routine clinical diagnostic evaluation, patients who are admitted to the HRF with a suspect of TB, received a three sample sputum analysis and a thorax X-Ray. Ziehl-Neelsen’s sputum staining technique is used, and patients are considered smear positive if acid fast bacilli are shown on at least two samples. Sputum Culture and PCR are not available in the country for the present being. Smear negative patients are considered to have TB according to the physician’s evaluation of chest X-Ray and clinical condition. Additional analyses (complete blood count, biochemistry, urine and stool evaluation and culture) are performed if necessary, based on physician’s judgment. TB is treated according to the National Guidelines, with a four drug regimen for two months (rifampicin, isoniazid, ethambutol and pyrazinamide) followed by two drugs for the following six months (isoniazid and ethambutol); five drugs are used in case of relapsed TB (streptomycin, rifampicin, isoniazid, ethambutol and pyrazinamide).

We evaluated all-cause mortality rates, adherence to the hospitalization phase of TB treatment, diagnostic procedures and direct costs for inpatients in the first 5 months of the public-private management (October 1st 2012-February 28th 2013); furthermore, we compared them to the five months of the same season in previous years (October 1st 2009-February 28th 2010), when complete data were available. Data on TB co-infections or hematologic malignancies and severity score were seldom available and not routinely utilized to grade and classify patients in both periods and therefore could not be compared. No user fees were applied during the public-private management while user fees were applied during previous years under the Government direct management of the hospital both during the diagnostic pathway and for admission. Patients’ clinical cards and hospital registries were used to cross-check diagnosis, therapy and admission-discharge dates. Pearson’s chi-square test was used to compare variables within groups. p-values<0.05 were considered statistically significant.

Results. The majority of patients came from Bissau (82% in 2009 and 71% in 2012); there was a slight increase in patients coming from outside the capital in 2012 (29 % vs 18%). No treatment abandonment was observed in the two periods, but 15 drop outs were registered between January 2009 and May 2012 –when user fees were applied- and only 1 between June 2012 and May 2013 –when treatment was free.
The clinical characteristics of admitted inpatients are detailed in Table 1.

A significant reduction in mortality (21 vs 6%) was observed in October 2012-February 2013, both during the first week of admission and afterwards (Table 1 and Table 2). Within the population of patients who died, the number of diagnostic exams was significantly different, with improved quality of

| Table 1. Main clinical characteristics and outcomes of admitted inpatients to HRF | October 2009-February 2010 | October 2012-February 2013 | p-value |
|---|---|---|---|
| Admissions | 215 | 194 | 0.6 |
| Gender | | | |
| M | 132 | 110 | |
| F | 83 | 84 | |
| Mean Age (years) | 39 | 32 | 0.9 |
| Diagnosis of TB at admission (%) | | | |
| New Diagnosis | 175 | 167 | 0.2 |
| Relapse | 5 | 6 | |
| Not Known | 35 | 21 | |
| Type of TB at admission | | | |
| Pulmonary TB Smear + | 100 | 122 | 0.1 |
| Pulmonary TB Smear – | 54 | 5 | |
| ExtraPulmonary TB | 11 | 16 | |
| Other | 50 | 52 | |
| HIV status | | | |
| Positive | 66 | 82 | 0.05 |
| HIV1 | 40 | 49 | |
| HIV2 | 6 | 5 | |
| HIV1+2 | 20 | 28 | |
| Negative | 92 | 104 | |
| Not done | 57 | 8 | |
| On treatment | 0 | 7 | |
| Deaths | | | |
| Number of Deaths | 24 | 22 | 0.01 |
| M:F | 4:2 | 8:8 | |
| Mean Age (years) | 39.3 | 44 | 0.1 |
| Mean Lenght of Stay (days) | 3 | 30.4 | 0.04 |
| TB Diagnosis at admission | | | |
| Pulmonary TB Smear + | 4 | 4 | |
| Pulmonary TB Smear – | 3 | 3 | 0.01 |
| ExtraPulmonary TB | - | - | |
| Other | 4 | - | |
| Not known | 12 | 15 | |
| Symptoms at admission | | | |
| Fever | 6 | 5 | 0.001 |
| Convulsions | 1 | - | |
| Respiratory distress | 4 | 1 | |
| Other | - | 2 | |
| Not Known | 13 | 37 | |
| Clinical Diagnosis of death | | | |
| Hemoptysis | - | 1 | |
| Cardio-respiratory failure | 2 | 3 | 0.002 |
| Malaria | 2 | 1 | |
| Fever | 4 | 4 | |
| Cancer (Kaposi Sarcoma) | - | 2 | |
| AIDS | - | - | |
| Not Known | 18 | 34 | |

| Table 2. Main clinical characteristics of inpatients who died, during the first week of admission and after the first week of admission | October 2009-February 2010 | October 2012-February 2013 | p-value |
|---|---|---|---|
| Number of Deaths | 24 | 22 | 0.01 |
| M:F | 4:2 | 8:8 | |
| Mean Age (years) | 39.3 | 44 | 0.1 |
| Mean Lenght of Stay (days) | 3 | 30.4 | 0.04 |
| TB Diagnosis at admission | | | |
| Pulmonary TB Smear + | 4 | 4 | |
| Pulmonary TB Smear – | 3 | 3 | 0.01 |
| ExtraPulmonary TB | - | - | |
| Other | 4 | - | |
| Not known | 12 | 15 | |
| Symptoms at admission | | | |
| Fever | 6 | 5 | 0.001 |
| Convulsions | 1 | - | |
| Respiratory distress | 4 | 1 | |
| Other | - | 2 | |
| Not Known | 13 | 37 | |
| Clinical Diagnosis of death | | | |
| Hemoptysis | - | 1 | |
| Cardio-respiratory failure | 2 | 3 | 0.002 |
| Malaria | 2 | 1 | |
| Fever | 4 | 4 | |
| Cancer (Kaposi Sarcoma) | - | 2 | |
| AIDS | - | - | |
| Not Known | 18 | 34 | |

Mediterr J Hematol Infect Dis 2014; 6: Open Journal System
diagnostic pathway in October 2012-February 2013 compared to October 2009-February 2010 (Figure 1 A-B). This allowed a significant increase in the number of patients in which the cause of death could be determined (Table 2).

The number and type of available drugs was also different in the two periods with increased availability of i.v. antibiotics and antimalarials in 2012-2013 compared to 2009-2010 (1.6 vs 0.2 per patient).

Direct costs of TB diagnosis (XRays, BK analysis, Laboratory exams) in October 2009-February 2010 were 31000 CFA per patient (65,11 USD) while in October 2012-February 2013 they were zero. No direct cost for hospitalization was required in October 2012-February 2013 while in October 2009-February 2010 they were estimated in 195000 CFA per patient (409,5 USD) (bed occupation, food, non specific drugs).

Discussion. Our experience suggests that a public-private partnership within the framework of the National TB Program in a National Reference Center, can be successfully implemented in a low resource and post-conflict country. Even if a six months period is too short to evaluate long term indicators, significant reductions in mortality and improvements in diagnosis can already be observed in the short term.

In-hospital mortality for TB patients is multifactorial and remains high in many countries.9 The significant reduction in mortality (21 vs 6%) observed in our cohort was due to the reduction of mortality both during the first week of admission and afterwards. Patients, usually admitted in severe conditions, frequently have disseminated infections or comorbidities. It is likely that patients have sought care earlier in the course of the disease, knowing it was free of charge. Moreover, the increased availability of diagnostic tools, iv antibiotics, antimalarials and saline solutions might have had an impact in the possibility of physicians to manage acutely ill patients and therefore contributed to the mortality reduction both in the first week of admission and afterwards.10 No treatment default was observed since the free hospitalization regimen was implemented; meaning that lack of will to be cured is not an issue. TB patients in Africa often default in the hospitalization phase: hospitalization is problematic due to poor general conditions in TB hospitals, costs incurred by patients during hospitalisation and because patients need to earn living or take care of their families.11 Stock ruptures, shortage of reagents and drugs and low salaries produce lack of motivation and poor morale impairing health personnel’s work and dramatically reducing diagnostic and treatment performances in Africa. The free care of severely ill TB patients, including drugs and nutritional support, coupled with top-up for the personnel is likely to have contributed to eliminate drop outs and reduce mortality after the first week of admission.

Our short term analysis has several limits. First, we considered all cause mortality and could not detail TB related mortality, mainly due to the limited number of diagnostic exams performed in the first period. It is likely that considering complete blood count and other laboratory exams on a routine basis will allow a better definition of other causes of mortality in TB inpatients such as acute anemia, concomitant infections, hematologic malignancies, etc. Second, the direct cost that were evaluated included the costs that are necessary for TB diagnosis and inpatient care and not all the direct cost that the patients experience, therefore they are probably underestimated and overall direct costs are likely to be higher in both periods. Third, a short term evaluation of public private partnership in only five months does not allow detailing all the
benefits and drawbacks of such a collaboration. Nevertheless, post conflict and low resource countries such as Guinea-Bissau that do not seem able to find rational and appropriate ways to come out of isolation and to tackle health challenges, desperately need positive experiences. We think it’s worth reporting the improvement obtained in a short period of time of a public-private international partnership in order to move forward and enhance TB diagnosis, definition of co-morbidities, treatment and care in the long term.

Conclusion. The main challenge in fighting the TB epidemics in Sub-Saharan Africa is to improve the sanitary system. Our experience demonstrates that international public-private partnerships in TB hospital settings can contribute, in the short term, to increase adherence to the hospitalization phase of intensive treatment, improve quality of diagnosis and care and reduce mortality through a free pathway of diagnosis and care.12

Acknowledgments. The Authors would like to thank the Ministry of Health, the National Program Against Tuberculosis, the staff of the Hospital Raoul Follereau and all the patients and their families.

References:
1. World Health Tuberculosis, Global Tuberculosis Report 2013
2. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011 Jul 2;378(9785):57-72. doi: 10.1016/S0140-6736(10)62173-3. Epub 2011 Mar 21. http://dx.doi.org/10.1016/S0140-6736(10)62173-3
3. Baloch NA, Pai M. Tuberculosis control: business models for the private sector. Lancet Infect Dis. 2012 Aug;12(8):579-80. http://dx.doi.org/10.1016/S1473-3099(12)70122-6
4. Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health. 2011 May 26;11:393. http://dx.doi.org/10.1186/1471-2458-11-393 PMid:21615930
5. Luq Q, Smith H, Wang Y, Tang S, Wang Q, Garner P. Tuberculosis patient expenditure on drugs and tests in subsidised, public services in China: a descriptive study. Trop Med Int Health. 2010 Jan;15(1):26-32. Epub 2009 Nov 16. PMid:19917035
6. Barter DM, Agboola SO, Murray MB, Bärnighausen T. Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa—a systematic review. BMC Public Health. 2012 Nov 14;12:980. http://dx.doi.org/10.1186/1471-2458-12-980 PMid:23150901
7. Santana RM. Revisão das Despesas do sector da saúde: relatório preliminar. Banco Mundial Ministério da Saúde Pública da República da República da Guiné-Bissau. Outubro de 2007
8. Programa Nacional de Luta contra a Tuberculose. Manual de Tratamento 2010. Bissau, Guinea Bissau.
9. Kyeyune R, den Boon S, Cattamanchi A, Davis JL, Worodria W, Yoo SD, Huang L. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr. 2010 Dec;55(4):446-50. http://dx.doi.org/10.1097/QAI.0b013e3181eb611a PMid:21105258 PMCid:PMC3249444
10. Colombatti R, Penazzato M, Bassani F, Vieira CS, Lourenço AA, Vieira F, Teso S, Giuquinto C, Riccardi F. Malaria prevention reduces in-hospital mortality among severely ill tuberculosis patients: a three-step intervention in Bissau, Guinea-Bissau. BMC Infect Dis. 2011 Mar 2;11:57. http://dx.doi.org/10.1186/1471-2234-11-57 PMid:2136907 PMCid:PMC3056796
11. Irebunandu NA, Ukwaja KN. Tuberculosis treatment default in a large tertiary care hospital in urban Nigeria: prevalence, trend, timing and predictors. J Infect Public Health. 2012 Oct;5(5):340-5. http://dx.doi.org/10.1016/j.jiph.2012.06.002
12. Khan AJ, Khwaja S, Khan FS, Qazi F, Lotia I, Habib A, Mohamed S, Khan U, Amanullah F, Hussain H, Becerra MC, Creswell J, Keshavjee S. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. Lancet Infect Dis. 2012 Aug;12(8):608-16. http://dx.doi.org/10.1016/S1473-3099(12)70116-0